1. Intermittent Treatment with Azithromycin and Ethambutol for Noncavitary Mycobacterium avium Complex Pulmonary Disease.
- Author
-
Moon SM, Yoo IY, Huh HJ, Lee NY, and Jhun BW
- Subjects
- Body Mass Index, Drug Therapy, Combination methods, Female, Humans, Lung Diseases microbiology, Male, Mycobacterium avium-intracellulare Infection drug therapy, Odds Ratio, Treatment Outcome, Antitubercular Agents therapeutic use, Azithromycin therapeutic use, Ethambutol therapeutic use, Mycobacterium avium Complex drug effects, Mycobacterium avium Complex pathogenicity
- Abstract
We evaluated the efficacy of intermittent azithromycin and ethambutol therapy for noncavitary Mycobacterium avium complex pulmonary disease (MAC-PD). Twenty-nine (76%) of 38 patients achieved sputum culture conversion after 12 months of treatment, and sputum smear positivity was an independent factor for failure to achieve culture conversion (adjusted odds ratio, 26.7; 95% confidence interval, 2.1 to 339.9; P = 0.011). Intermittent azithromycin and ethambutol may be an optional treatment regimen for noncavitary MAC-PD., (Copyright © 2019 American Society for Microbiology.)
- Published
- 2019
- Full Text
- View/download PDF